TLDR AbbVie reported Q4 adjusted earnings of $2.71 per share, beating analyst expectations of $2.65 Revenue reached $16.6 billion in the quarter, surpassing theTLDR AbbVie reported Q4 adjusted earnings of $2.71 per share, beating analyst expectations of $2.65 Revenue reached $16.6 billion in the quarter, surpassing the

AbbVie (ABBV) Stock: Why Shares Are Falling Despite Earnings Beat and Strong 2026 Guidance

3 min read

TLDR

  • AbbVie reported Q4 adjusted earnings of $2.71 per share, beating analyst expectations of $2.65
  • Revenue reached $16.6 billion in the quarter, surpassing the $16.4 billion estimate
  • 2026 adjusted earnings guidance of $14.37 to $14.57 per share tops consensus view of $14.27
  • Oncology revenue dropped 2.5% and aesthetics revenue fell 1.2% on an operational basis
  • Humira sales plunged 26% to $1.2 billion as biosimilar competition intensifies after 2023 patent loss

AbbVie shares dropped 3.6% on Wednesday despite the drugmaker posting solid quarterly results and upbeat guidance for the year ahead. The stock’s decline came even as the company topped Wall Street estimates across key metrics.

The pharmaceutical company reported adjusted earnings of $2.71 per share for the fourth quarter. That beat analyst expectations of $2.65 per share. Revenue came in at $16.6 billion, topping the $16.4 billion consensus estimate.


ABBV Stock Card
AbbVie Inc., ABBV

For 2026, AbbVie issued guidance that exceeded market expectations. The company expects adjusted earnings between $14.37 and $14.57 per share. Analysts had predicted $14.27 per share.

But investors focused on weakness in certain business segments. Oncology revenue hit $1.7 billion in the quarter, down 2.5% on an operational basis. The aesthetics portfolio, which includes Botox Cosmetic and Juvederm, generated $1.3 billion in revenue, falling 1.2% operationally.

Immunology Growth Led by Skyrizi and Rinvoq

The immunology portfolio delivered strong performance with $8.6 billion in revenue, up more than 18% from the prior year. Skyrizi recorded sales of $5.01 billion, growing 32.5% and beating estimates of $4.82 billion. Rinvoq sales grew 29.5% to $2.37 billion, though slightly missing estimates of $2.41 billion.

These newer immunology drugs are filling the gap left by Humira. The once-blockbuster drug saw revenue fall 26% to $1.2 billion in the quarter. However, this figure surprisingly beat analyst estimates of $983.8 million, marking the first time in nearly two years that Humira sales exceeded expectations.

Humira lost market exclusivity in 2023. The drug now faces fierce competition from biosimilars, which are near copies of biological drugs sold at lower prices. At its peak in 2022, Humira generated more than $21 billion in global sales.

Botox Cosmetic Shows First Growth Since Q3 2024

The aesthetics business showed signs of life. Botox Cosmetic sales reached $717 million, beating estimates of $696.2 million. This marked the first revenue growth since the third quarter of 2024.

Demand for the anti-wrinkle injection has been pressured by customer concerns about the economy and inflation. New competition from companies like Revance and Evolus has also eaten into market share.

AbbVie has been actively investing to drive future growth. The company has spent more than $20 billion on acquisitions recently. It plans to invest another $10 billion over the next decade, including building four new manufacturing plants in the United States.

The stock’s weakness came even as the broader market edged higher. Futures tracking the S&P 500 rose 0.1% in morning trading. Fellow drugmaker Eli Lilly gained 9% after reporting its own strong earnings results.

Shares briefly rose in premarket trading before reversing course. The decline suggests investors remain concerned about revenue pressures in oncology and aesthetics despite the company’s overall financial strength.

AbbVie’s Q4 adjusted earnings of $2.71 per share and revenue of $16.6 billion both exceeded Wall Street expectations, while 2026 guidance of $14.37 to $14.57 per share topped the $14.27 consensus estimate.

The post AbbVie (ABBV) Stock: Why Shares Are Falling Despite Earnings Beat and Strong 2026 Guidance appeared first on Blockonomi.

Market Opportunity
Audiera Logo
Audiera Price(BEAT)
$0.18
$0.18$0.18
-3.41%
USD
Audiera (BEAT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Trading time: Tonight, the US GDP and the upcoming non-farm data will become the market focus. Institutions are bullish on BTC to $120,000 in the second quarter.

Daily market key data review and trend analysis, produced by PANews.
Share
PANews2025/04/30 13:50
Ethereum Fusaka Upgrade Set for December 3 Mainnet Launch, Blob Capacity to Double

Ethereum Fusaka Upgrade Set for December 3 Mainnet Launch, Blob Capacity to Double

Ethereum developers confirmed the Fusaka upgrade will activate on mainnet on December 3, 2025, following a systematic testnet rollout beginning on October 1 on Holesky. The major hard fork will implement around 11-12 Ethereum Improvement Proposals targeting scalability, node efficiency, and data availability improvements without adding new user-facing features. According to Christine Kim, the upgrade introduces a phased blob capacity expansion through Blob Parameter Only forks occurring two weeks after Fusaka activation. Initially maintaining current blob limits of 6/9 target/max, the first BPO fork will increase capacity to 10/15 blobs one week later. A second BPO fork will further expand limits to 14/21 blobs, more than doubling total capacity within two weeks. Strategic Infrastructure Overhaul Fusaka prioritizes backend protocol improvements over user-facing features, focusing on making Ethereum faster and less resource-intensive. The upgrade includes PeerDAS implementation through EIP-7594, allowing validator nodes to verify data by sampling small pieces rather than downloading entire blobs. This reduces bandwidth and storage requirements while enhancing Layer 2 rollup scalability. The upgrade builds on recent gas limit increases from 30 million to 45 million gas, with ongoing discussions for further expansion. EIP-7935 proposes increasing limits to 150 million gas, potentially enabling significantly higher transaction throughput. These improvements complement broader scalability efforts, including EIP-9698, which suggests a 100x gas limit increase over two years to reach 2,000 transactions per second. Fusaka removes the previously planned EVM Object Format redesign to reduce complexity while maintaining focus on essential infrastructure improvements. The upgrade introduces bounded base fees for blob transactions via EIP-7918, creating more predictable transaction costs for data-heavy applications. Enhanced spam resistance and security improvements strengthen network resilience against scalability bottlenecks and attacks. Technical Implementation and Testing Timeline The Fusaka rollout follows a conservative four-phase approach across Ethereum testnets before mainnet deployment. Holesky upgrade occurs October 1, followed by Sepolia on October 14 and Hoodi on October 28. Each testnet will undergo the complete BPO fork sequence to validate the blob capacity expansion mechanism. BPO forks activate automatically based on predetermined epochs rather than requiring separate hard fork processes. On mainnet, the first BPO fork launches December 17, increasing blob capacity to 10/15 target/max. The second BPO fork activates January 7, 2026, reaching the final capacity of 14/21 blobs. This automated approach enables flexible blob scaling without requiring full network upgrades. Notably, node operators face release deadlines ranging from September 25 for Holesky to November 3 for mainnet preparation. The staggered timeline, according to the developers, allows comprehensive testing while giving infrastructure providers sufficient preparation time. Speculatively, the developers use this backward-compatible approach to ensure smooth transitions with minimal disruption to existing applications. PeerDAS implementation reduces node resource demands, potentially increasing network decentralization by lowering barriers for smaller operators. The technology enables more efficient data availability sampling, crucial for supporting growing Layer 2 rollup adoption. Overall, these improvements, combined with increased gas limits, will enable Ethereum to handle higher transaction volumes while maintaining security guarantees. Addressing Network Scalability Pressures The Fusaka upgrade addresses mounting pressure for Ethereum base layer improvements amid criticism of Layer 2 fragmentation strategies. Critics argue that reliance on rollups has created isolated chains with limited interoperability, complicating user experiences. The upgrade’s focus on infrastructure improvements aims to enhance base layer capacity while supporting continued Layer 2 growth. The recent validator queue controversy particularly highlights ongoing network scalability challenges. According to a Cryptonews report covered yesterday, currently, over 2M ETH sits in exit queues facing 43-day delays, while entry queues process in just 7 days.Ethereum Validator Queue (Source: ValidatorQueue) However, Vitalik Buterin defended these delays as essential for network security, comparing validator commitments to military service requiring “friction in quitting.” The upgrade coincides with growing institutional interest in Ethereum infrastructure, with VanEck predicting that Layer 2 networks could reach $1 trillion market capitalization within six years. Fusaka’s emphasis on data availability and node efficiency supports Ethereum’s evolution toward seamless cross-chain interoperability. The upgrade complements initiatives like the Open Intents Framework, where Coinbase Payments recently joined as a core contributor. The initiative, if successful, will address the $21B surge in cross-chain crime. These coordinated efforts aim to unify the fragmented multichain experience while maintaining Ethereum’s security and decentralization principles
Share
CryptoNews2025/09/19 16:37
VectorUSA Achieves Fortinet’s Engage Preferred Services Partner Designation

VectorUSA Achieves Fortinet’s Engage Preferred Services Partner Designation

TORRANCE, Calif., Feb. 3, 2026 /PRNewswire/ — VectorUSA, a trusted technology solutions provider, specializes in delivering integrated IT, security, and infrastructure
Share
AI Journal2026/02/05 00:02